Validation of the cardiac damage classification and additional effects of albumin levels in a large cohort of patients undergoing transcatheter aortic valve replacement

2 September 2019 (12:40 - 13:30)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Anat Berkovitch

Chaim Sheba Medical Center, Ramat Gan (Israel)

5 More presentations in this session

Presentation thumbnail

Mortality of surgical redo aortic valve replacement versus transcatheter aortic valve-in-valve implantation in patients with degenerated aortic bioprosthesis: a meta-analysis.

Doctor A. Pardo Sanz (Madrid, ES)

Abstract Slides

Presentation thumbnail

Incidence, risk factors and impact of readmission for heart failure after successful transcatheter aortic valve replacement

Doctor P. Guedeney (Paris, FR)

Abstract Slides

Presentation thumbnail

Timing and associated predictors of onset of new conduction disturbances requiring permanent pacemaker implantation after transcatheter aortic valve implantation

Miss N. Kooistra (Utrecht, NL)

Presentation thumbnail

High H2FPEF score is an independent predictor of adverse outcome in patients with severe aortic stenosis and preserved ejection fraction undergoing TAVR

Doctor S. Ludwig (Hamburg, DE)

Abstract Slides

Presentation thumbnail

Stroke after transcatheter aortic valve implantation: an unpredictable risk?

Mr G. Bosbach (Duesseldorf, DE)

Abstract Slides

Access the full session

Session thumbnail

TAVR outcomes: the future is here

The Event

ESC Congress 2019

2 September 2019 12:40 CET

You may be interested in

Congress Presentation

Aortic regurgitation and stenosis: diagnosis and mode of intervention

Congress Session

Failing valves and beyond

Congress Session

Controversies in heart valve disease: integrating art, science, medicine, and surgery into decision-making

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources